Oxetanes are used in drug discovery to enable physicochemical and metabolic property enhancement for the structures to which they are grafted. An imide CO to oxetane swap on thalidomide and lenalidomide templates provides analogs with similar physicochemical and <i>in vitro</i> properties of the parent drugs, with an important exception: oxetane analog <b>2</b> displays a clear differentiation with respect to human plasma stability. The prospect of limiting <i>in vivo</i> stability/metabolism, blocking <i>in vivo</i> racemization, and potentially altering teratogenicity is appealing